129 related articles for article (PubMed ID: 9365453)
1. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
[No Abstract] [Full Text] [Related]
2. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
3. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy.
Ezquerra GM; Redonnet MS; Cuchillero RO; Millet PU
J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):901-2. PubMed ID: 16898935
[No Abstract] [Full Text] [Related]
6. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
Wernz JC
AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
[No Abstract] [Full Text] [Related]
7. Liposomal doxorubicin (Doxil).
Porche DJ
J Assoc Nurses AIDS Care; 1996; 7(2):55-9. PubMed ID: 8679968
[No Abstract] [Full Text] [Related]
8. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Hjortsberg C; Persson U; Lidbrink E; Bennett C
Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
Chew T; Jacobs M
Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
[TBL] [Abstract][Full Text] [Related]
11. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
12. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
13. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
Poizot-Martin I; Giovannini M; Rosello R; Viallat JR; Sauniere JF; Dalmas AM; Genre D; Dhiver C; Gastaut JA
J Clin Oncol; 1994 Mar; 12(3):645. PubMed ID: 8120565
[No Abstract] [Full Text] [Related]
14. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel for treating KS.
Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
[TBL] [Abstract][Full Text] [Related]
16. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
17. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
[No Abstract] [Full Text] [Related]
19. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
[No Abstract] [Full Text] [Related]
20. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G
Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
